\n<\/p>\n
“We’re thrilled that ABRYSVO is now accredited within the EU to assist stop RSV in adults aged 18 and older, which causes roughly 158,000 grownup hospital admissions yearly from RSV illness, a typical respiratory virus with signs that may be extreme and even life-threatening,” mentioned Alexandre de Germay, Chief Worldwide Business Officer, Govt Vice President, Pfizer<\/a>. “With a sign that additionally contains pregnant people between weeks 24 and 36 gestation to assist shield infants from start as much as 6 months of age, ABRYSVO’s expanded authorization for adults aged 18 to 59 within the EU signifies one other step for public well being by providing the potential to considerably cut back the burden of RSV in future seasons.” <\/p>\n The amended advertising authorization follows the current constructive opinion <\/a> from the Committee for Medicinal Merchandise for Human Use (CHMP). The authorization is legitimate in all 27 EU member states plus Iceland, Liechtenstein, and Norway. The approval relies on outcomes from the pivotal section 3 medical trial ( NCT05842967 <\/a> ) MONeT <\/b> (RSV I M <\/b> munizati ON <\/b> Research for Adul T <\/b> s at Larger Threat of Extreme Sickness), which investigated the protection, tolerability, and immunogenicity of ABRYSVO in adults 18 via 59 years of age susceptible to RSV-associated LRTD attributable to sure persistent medical situations. It was additionally supported by the 1000’s of individuals vaccinated in medical trials involving ABRYSVO on this age group. 1,2,3,4 <\/sup> The outcomes of MONeT and different research have been printed in peer-reviewed journals. <\/p>\n ABOUT RSV ABOUT ABRYSVO In August 2023, Pfizer<\/a>\u00a0 introduced <\/a> that the European Fee granted advertising authorization for ABRYSVO for each adults aged 60 years and older and maternal immunization to assist shield infants. <\/p>\n In the usin October 2024, the FDA accredited <\/a> ABRYSVO for the prevention of decrease respiratory tract illness brought on by RSV in people 18 via 59 years of age who’re at elevated danger for LRTD brought on by RSV. Prior, in Might 2023, the FDA accredited <\/a> ABRYSVO for the prevention of LRTD brought on by RSV in people 60 years of age and older. In August 2023, the FDA accredited <\/a> ABRYSVO for the prevention of LRTD and extreme LRTD brought on by RSV in infants from start as much as 6 months of age by lively immunization of pregnant people at 32 via 36 weeks gestational age. <\/p>\n Along with the newest EU approval, ABRYSVO has acquired approvals for each indications in a number of international locations worldwide. <\/p>\n U.S. INDICATIONS FOR ABRYSVO <\/b><\/p>\n ABRYSVO \u00ae <\/sup> is a vaccine indicated within the U.S. for: <\/b><\/p>\n IMPORTANT U.S. SAFETY INFORMATION FOR ABRYSVO <\/b><\/p>\n View the total ABRYSVO Prescribing Data <\/b><\/a> . <\/b><\/p>\n About Pfizer<\/a>: Breakthroughs That Change Sufferers’ Lives DISCLOSURE NOTICE: This launch comprises forward-looking details about ABRYSVO, together with its potential advantages and an approval within the EU to increase the indication to incorporate prevention of LRTD brought on by RSV in people 18 via 59 years of age, that entails substantial dangers and uncertainties that would trigger precise outcomes to vary materially from these expressed or implied by such statements. Dangers and uncertainties embrace, amongst different issues, uncertainties relating to the business success of ABRYSVO; the uncertainties inherent in analysis and growth, together with the flexibility to fulfill anticipated medical endpoints, graduation and\/or completion dates for our medical trials, regulatory submission dates, regulatory approval dates and\/or launch dates, in addition to the potential for unfavorable new medical knowledge and additional analyses of current medical knowledge; dangers related to interim knowledge; the danger that medical trial knowledge are topic to differing interpretations and assessments by regulatory authorities; whether or not regulatory authorities can be happy with the design of and outcomes from our medical research; whether or not and when biologic license purposes could also be filed particularly jurisdictions for ABRYSVO for any potential indications; whether or not and when any purposes that could be pending or filed for ABRYSVO could also be accredited by regulatory authorities, which is able to depend upon myriad elements, together with making a willpower as as to whether the product’s advantages outweigh its identified dangers and willpower of the product’s efficacy and, if accredited, whether or not ABRYSVO for any such indications can be commercially profitable; mental property and different litigation; selections by regulatory authorities impacting labeling, manufacturing processes, security and\/or different issues that would have an effect on the supply or business potential of ABRYSVO; uncertainties relating to the flexibility to acquire or keep suggestions from vaccine advisory or technical committees and different public well being authorities relating to ABRYSVO and uncertainties relating to the business impression of any such suggestions; uncertainties relating to the impression of COVID-19 on our enterprise, operations and monetary outcomes; and aggressive developments. <\/i><\/p>\n An extra description of dangers and uncertainties might be present in Pfizer<\/a>‘s Annual Report on Kind 10-Okay for the fiscal 12 months ended December 31, 2024, and in its subsequent experiences on Kind 10-Q, together with within the sections thereof captioned “Threat Elements” and “Ahead-Trying Data and Elements That Might Have an effect on Future Outcomes”, in addition to in its subsequent experiences on Kind 8-Okay, all of that are filed with the U.S. Securities and Change Fee and out there at <\/i> www.sec.gov <\/i><\/a> and <\/i> www.<\/i><\/a>Pfizer<\/a>.com <\/i>\u00a0 . <\/i><\/p>\n 1 <\/sup> Walsh EE, Falsey AR, Scott DA, et al. A Randomized Part 1\/2 Research of a Respiratory Syncytial Virus Prefusion F Vaccine. J Infect Dis. 2022 Apr 19;225(8):1357-1366. <\/p>\n 2 <\/sup> Schmoele-Thoma B, Zareba AM, Jiang Q, et al. Vaccine Efficacy in Adults in a Respiratory Syncytial Virus Problem Research. N Engl J Med. 2022 Jun 23;386(25):2377-2386. doi: 10.1056\/NEJMoa2116154. <\/p>\n 3 <\/sup> Baker J, Aliabadi N, Munjal I, et al. Equal immunogenicity throughout three RSVpreF vaccine tons in wholesome adults 18-49 years of age: Outcomes of a randomized section 3 examine. Vaccine. 2024 Might 10;42(13):3172-3179. doi: 10.1016\/j.vaccine.2024.03.070. Epub 2024 Apr 16. <\/p>\n 4 <\/sup> Peterson JT, Zareba AM, Fitz-Patrick D, et al. Security and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine. J Infect Dis. 2022 Jun 15;225(12):2077-2086. doi: 10.1093\/infdis\/jiab505. <\/p>\n 5 <\/sup> World Well being Group. Respiratory Syncytial Virus (RSV) illness. https:\/\/www.who.int\/groups\/health-product-policy-and-standards\/standards-and-specifications\/vaccine-standardization\/respiratory-syncytial-virus-disease <\/a><\/p>\n 6 <\/sup> World Well being Group. Respiratory Syncytial Virus (RSV). https:\/\/www.who.int\/news-room\/fact-sheets\/element\/respiratory-syncytial-virus-(rsv) <\/a><\/p>\n 7 <\/sup> Facilities for Illness Management and Prevention. Respiratory Syncytial Virus An infection (RSV) \u2013 Older Adults are at Excessive Threat for Extreme RSV An infection Reality Sheet. https:\/\/www.cdc.gov\/rsv\/factsheet-older-adults.pdf <\/a><\/p>\n 8 <\/sup> Facilities for Illness Management and Prevention. RSV in Infants and Younger Youngsters. https:\/\/www.cdc.gov\/rsv\/high-risk\/infants-young-children.html <\/p>\n 9 <\/sup> Nuttens C, Moyersoen J, Curcio D, et al. Variations Between RSV A and RSV B Subgroups and Implications for Pharmaceutical Preventive Measures. Infect Dis Ther <\/i> . 2024;13(8):1725-1742. doi:10.1007\/s40121-024-01012-2 <\/p>\n 10 <\/sup> Del Riccio M, Spreeuwenberg P, Osei-Yeboah R, et al. Estimation of the Variety of Respiratory Syncytial Virus\u2013Related Hospitalizations in Adults within the European Union. <\/a> J Infect Dis 2023 Might 29;228(11):1539\u20131548. doi: 10.1093\/infdis\/jiad189 <\/a> . <\/p>\n View supply model on businesswire.com: <\/span> https:\/\/www.businesswire.com\/information\/residence\/20250331970714\/en\/ <\/a><\/span><\/p>\n Media Contact: Investor Contact:
<\/b> Respiratory Syncytial Virus (RSV) is a contagious virus and a typical explanation for respiratory sickness worldwide. 5 <\/sup> The virus can have an effect on the lungs and respiration passages of an contaminated particular person, doubtlessly inflicting extreme sickness or dying. 6,7,8 <\/sup> There are two main subgroups of RSV: RSV-A and RSV-B. 9 <\/sup> Each subgroups trigger illness and might co-circulate or alternate predominance from season to season. In whole, RSV causes roughly 158,000 hospital admissions yearly amongst adults aged 18 and older throughout the EU, with an estimated 13,000 hospitalizations in these aged 18 to 64 years. 10 <\/sup><\/p>\n
<\/b> ABRYSVO is an unadjuvanted, bivalent vaccine that was designed to supply safety towards RSV-LRTD, whatever the virus subgroup. Within the prefusion state, the RSV fusion protein (F) is a significant goal of neutralizing antibodies, serving as the premise of Pfizer<\/a>‘s RSV vaccine. Variations within the F protein sequence amongst RSV-A and RSV-B subgroups are clustered in a key antigenic website, a goal for potent neutralizing antibodies. <\/p>\n\n
\n
<\/b> At Pfizer<\/a>, we apply science and our world assets to carry therapies to folks that reach and considerably enhance their lives. We attempt to set the usual for high quality, security, and worth within the discovery, growth, and manufacture of well being care merchandise, together with revolutionary medicines and vaccines. On daily basis, Pfizer<\/a> colleagues work throughout developed and rising markets to advance wellness, prevention, therapies, and cures that problem essentially the most feared illnesses of our time. In step with our duty as one of many world’s premier revolutionary biopharmaceutical corporations, we collaborate with well being care suppliers, governments, and native communities to assist and broaden entry to dependable, inexpensive well being care all over the world. For 175 years, we’ve labored to make a distinction for all who depend on us. We routinely put up info that could be necessary to traders on our web site at www.Pfizer.com <\/a> . As well as, to be taught extra, please go to us on www.Pfizer.com <\/a> and comply with us on X at @Pfizer <\/a> and @Pfizer Information <\/a> , LinkedIn <\/a> , YouTube <\/a> , and like us on Fb at Fb.com\/Pfizer <\/a> . <\/p>\n
<\/i><\/b> The knowledge contained on this launch is as of April 1, 2025. Pfizer<\/a> assumes no obligation to replace forward-looking statements contained on this launch as the results of new info or future occasions or developments. <\/i><\/p>\n
PfizerMediaRelations@Pfizer.com <\/a>
+1 (212) 733-1226 <\/p>\n
IR@Pfizer.com <\/a>
+1 (212) 733-4848 <\/p>\n<\/div>\n